Skip to main content
AYTU BIOPHARMA, INC logo

AYTU BIOPHARMA, INC — Investor Relations & Filings

Ticker · AYTU ISIN · US0547548745 US Manufacturing
Open in API
Filings indexed 890 across all filing types
Latest filing 2022-09-21 Proxy Solicitation & In…
Country US United States of America
Listing US AYTU

About AYTU BIOPHARMA, INC

https://aytubio.com/

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing novel therapeutics. The company concentrates on advancing innovative medicines for complex central nervous system (CNS) diseases, with a particular emphasis on treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) and Major Depressive Disorder (MDD). Its business model involves identifying, acquiring, and commercializing new products to improve the quality of life for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed with the SEC. It includes a reminder letter urging shareholders to vote on proposals for a special meeting. The text references proxy materials, voting instructions, and solicitation of votes, which are typical of Proxy Solicitation & Information Statements. The document is not the proxy statement itself but additional materials related to the proxy solicitation. The document length is short (2856 characters), and it is clearly a solicitation and reminder for voting, not a full report or financial statement. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI).
2022-09-21 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Aytu BioPharma, Inc. It announces the upcoming release date of the company's financial results for the fourth quarter and fiscal year ended June 30, 2022, and the scheduling of a conference call to discuss these results. The document does not contain the actual financial results or detailed financial statements but rather serves as a notification of the forthcoming earnings release and conference call. The document length is 3131 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as an Earnings Release (ER) announcement, as it informs about the timing of the earnings release and related call but does not include the earnings data itself.
2022-09-20 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the announcement of a new patent addition to the company's intellectual property portfolio. There are no financial statements or detailed financial data included, and the document is relatively short (3345 characters). It is primarily an announcement of a corporate event rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-09-14 English
DEF 14A
Proxy Solicitation & Information Statement
2022-08-25 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the issuance of a new patent by the U.S. Patent and Trademark Office, which is a significant corporate event but not a financial report or earnings release. The document includes a press release as an exhibit and does not contain financial statements or detailed financial data. The length is 3342 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. Therefore, this filing fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2022-08-16 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 15, 2022, reporting the closing of an underwritten public offering of common stock and warrants by Aytu BioPharma, Inc. The content focuses on the details of the financing transaction, including shares issued, warrants, gross proceeds, and total shares outstanding after the offering. There are no financial statements or comprehensive financial data presented, only an announcement of a capital raising event. This fits the definition of a Capital/Financing Update (CAP). The document length is 3557 characters, which is consistent with a typical 8-K announcement rather than a full report. Therefore, the appropriate classification is CAP with high confidence.
2022-08-15 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.